Ocugen Discloses Data And Safety Monitoring Board Approves Enrollment In High Dose Cohort 3 In Gardian Study For Stargardt Disease; Company Says It Established Medium Dose As Safe And Tolerable Dose In Current OCU410ST Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to enroll patients in the high dose cohort 3 of its Gardian study for Stargardt disease. The medium dose has been established as safe and tolerable in the ongoing OCU410ST clinical trial.
June 21, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocugen's Gardian study for Stargardt disease has progressed to the high dose cohort after the DSMB approved enrollment. The medium dose has been established as safe and tolerable, with no serious adverse events reported.
The approval to move to the high dose cohort in the Gardian study is a positive development for Ocugen, indicating progress in their clinical trial without serious adverse events. This could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100